The whole thing was summed up very succinctly at an asthma discussion group
(the great, the good, and me) where one consultant said to the company-type
person:
'Why isn't this drug a whole lot better than it actually is?'
Robert
Robert Treharne Jones
Marketing Director
Sullivan Cuff Software Ltd
Tel: +44 (1803) 605359
Email: [log in to unmask]
----------
> From: Adrian Midgley <[log in to unmask]>
> To: [log in to unmask]
> Subject: Monteleukast; Accolate
> Date: 06 October 1998 01:17
>
> Experience of two patients with Monteleukast so far.
>
> Child considerably improved while on it, now off for the second limb
> of an n of 1 trial (well, best I can do)
>
> Adult less apparent.
>
> There doesn't seem to be anything terribly complicated about it -
> one reads the physiology involved, reads the account of the action
> of the drug, identifies pateints not doing well on previous
> treatment who may benefit from it and prescribes, keeping a close
> eye and a few figures.
>
> Accolate now available, consider this in the same light I think.
>
>
> --- OffRoad 1.9r registered to Adrian Midgley
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|